MacroGenics pauses work on vobra duo ADC pending mature survival data

MacroGenics has pumped the brakes on vobramitamab duocarmazine (vobra duo), pausing investment in additional opportunities for the antibody-drug conjugate (ADC) until it has updated data from a phase 2 monotherapy prostate cancer trial.